TXG

83.60

7.15% 5.58

Handel nachbörslich: 85.38 1.78 +2.13%

10 X Genomics Inc (TXG)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$78.02

Offen:

$78.93

24-Stunden-Volumen:

4.37M

Relative Volume:

1.44

Marktkapitalisierung:

$10.89B

Einnahmen:

$638.78M

Nettoeinkommen (Verlust:

$-22.66M

KGV:

-479.36

EPS:

-0.1744

Netto-Cashflow:

$122.18M

1W Leistung:

+10.60%

1M Leistung:

-5.54%

6M Leistung:

+291.20%

1J Leistung:

+526.69%

1-Tages-Spanne:

$78.25

$87.82

1-Wochen-Bereich:

$67.25

$87.82

52-Wochen-Spanne:

$12.34

$102.81

10 X Genomics Inc Stock (TXG) Company Profile

Firmenname

10 X Genomics Inc

Sektor

Healthcare (1053)

Branche

Medical Devices (142)

Telefon

(925) 401-7300

Adresse

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Mitarbeiter

1,178

Twitter

@10xgenomics

Nächster Verdiensttermin

2026-11-05

Neueste SEC-Einreichungen

TXG's Discussions on Twitter

Compare TXG vs ABT, MDT, SYK, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TXG 10 X Genomics Inc	83.60	10.89B	638.78M	-22.66M	122.18M	-0.1744
ABT Abbott Laboratories	102.66	177.64B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	94.69	121.12B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	303.84	116.54B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	42.10	61.02B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	91.53	52.76B	6.30B	1.07B	1.09B	1.8406

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-10-23	Herabstufung	Stephens	Overweight → Equal-Weight
2026-09-28	Eingeleitet	Argus	Buy
2026-09-09	Fortgesetzt	UBS	Neutral
2026-09-01	Eingeleitet	RBC Capital Mkts	Sector Perform
2026-03-31	Hochstufung	William Blair	Mkt Perform → Outperform
2025-12-11	Herabstufung	Citigroup	Buy → Neutral
2025-12-02	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-09-11	Eingeleitet	Piper Sandler	Neutral
2025-02-13	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-09-03	Eingeleitet	Leerink Partners	Outperform
2024-07-22	Hochstufung	Jefferies	Hold → Buy
2024-07-18	Herabstufung	JP Morgan	Overweight → Neutral
2024-07-10	Herabstufung	Deutsche Bank	Buy → Hold
2024-06-27	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-06-25	Herabstufung	Guggenheim	Buy → Neutral
2024-06-03	Fortgesetzt	Jefferies	Hold
2024-05-01	Herabstufung	TD Cowen	Buy → Hold
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-12-12	Hochstufung	BofA Securities	Underperform → Neutral
2023-07-05	Fortgesetzt	JP Morgan	Overweight
2023-05-10	Eingeleitet	Barclays	Overweight
2023-03-31	Eingeleitet	Stephens	Overweight
2023-02-02	Eingeleitet	UBS	Neutral
2022-12-14	Eingeleitet	Deutsche Bank	Buy
2022-08-18	Herabstufung	Goldman	Neutral → Sell
2022-07-25	Eingeleitet	Canaccord Genuity	Buy
2022-07-15	Herabstufung	BofA Securities	Neutral → Underperform
2022-07-15	Herabstufung	William Blair	Outperform → Mkt Perform
2021-10-15	Fortgesetzt	Cowen	Outperform
2021-09-14	Herabstufung	BofA Securities	Buy → Neutral
2021-03-15	Eingeleitet	William Blair	Outperform
2020-12-02	Eingeleitet	Goldman	Neutral
2020-09-09	Eingeleitet	Morgan Stanley	Overweight
2020-07-10	Eingeleitet	Stifel	Buy
2020-03-05	Eingeleitet	Guggenheim	Buy
2020-01-07	Eingeleitet	Citigroup	Buy
2019-10-07	Eingeleitet	BofA/Merrill	Buy
2019-10-07	Eingeleitet	Cowen	Outperform
2019-10-07	Eingeleitet	JP Morgan	Overweight
2019-09-24	Eingeleitet	Evercore ISI	Outperform

Alle ansehen

10 X Genomics Inc Aktie (TXG) Neueste Nachrichten

Oct 20, 2026

Single Cell Sequencing Market Forecast to 2035: Services, Technologies, End-users, Applications, and Regions | 15% CAGR Drives Drug Discovery and Precision Medicine Growth - GlobeNewswire Inc.

Oct 20, 2026

Oct 15, 2026

TXG 10-Q & SEC FilingsYahoo Finance - Yahoo! Finance Canada

Oct 15, 2026

Oct 08, 2026

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research - Zacks Investment Research

Oct 08, 2026

Oct 07, 2026

ARK and Catherine D. Wood report ownership above 5% in 10x Genomics (TXG). - Stock Titan

Oct 07, 2026

Researchers plan to test whether cell-by-cell analysis can find leukemia left after treatment. - Stock Titan

Oct 07, 2026

Oct 06, 2026

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.

Oct 06, 2026

Sep 30, 2026

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises - Zacks Investment Research

Sep 30, 2026

Sep 24, 2026

10x genomics director Shehnaaz Suliman sells $464,667 in stock - Investing.com

Sep 24, 2026

Form 4 10X Genomics Inc For: 24 September By Investing.com - Investing.com India

Sep 24, 2026

10x genomics director Shehnaaz Suliman sells $464,667 in stock By Investing.com - Investing.com Canada

Sep 24, 2026

Form 4 10X Genomics Inc For: 24 September By Investing.com - Investing.com UK

Sep 24, 2026

10x genomics director Shehnaaz Suliman sells $464,667 in stock By Investing.com - Investing.com UK

Sep 24, 2026

Under a trading plan, a 10x Genomics (TXG) director sells 5,723 shares in five transactions. - Stock Titan

Sep 24, 2026

At $77.75 to $82.53 a share, 10x Genomics (TXG) CEO made five sales under a trading plan. - Stock Titan

Sep 24, 2026

10x Genomics Insider Sold Shares Worth $464,668, According to a Recent SEC Filing - Yahoo Finance

Sep 24, 2026

Sep 23, 2026

Korea's Lunit announces collaboration with 10x Genomics for AI-enabled pathology analysis of cancer - BioSpectrum Asia

Sep 12, 2026

Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - Yahoo Finance

Sep 12, 2026

Sep 11, 2026

10x Genomics (TXG) CFO Adam Taich Sells 46,388 Shares - GuruFocus

Sep 11, 2026

10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com Nigeria

Sep 11, 2026

10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com

Sep 11, 2026